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        CD4  +  CD25  +  Foxp3  +   regulatory T cells (T reg 
cells) are a key checkpoint of T cell activity and 
are largely responsible for the maintenance of 
peripheral self-tolerance (  1  –  4  ). Although their 
mechanism of action is not yet fully under-
stood, they regulate CD4 and CD8 T cell ac-
tivity in a cell-extrinsic manner, and their 
depletion results in greatly enhanced T cell re-
sponses to pathogens (  5  ), self-antigens (  1  ), and 
tumors (  6, 7  ). Increasing evidence for their role 
in fostering immune privilege in both mouse 
and human tumors (  8, 9  ) has fueled interest in 
attempts to interfere with their number or 
function for therapeutic benefi  t  (  10, 11  ). In 
preclinical tumor models, CD25-directed T 
reg cell depletion effi   ciently synergizes with a 
variety of immune-based approaches, but only 
when depletion occurs prior or close to the 
time of tumor challenge (  7, 12, 13  ). Therapeu-
tic T reg cell depletion (i.e., depletion after tu-
mor establishment, which is more relevant to 
the clinical setting) has either not been thor-
oughly studied or has generally failed to en-
hance other immunomodulatory approaches 
(  14, 15  ). Although there is no clear explanation 
for the lack of synergy, a common suggestion is 
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  Interference with inhibitory immunological checkpoints controlling T cell activation pro-
vides new opportunities to augment cancer immunotherapies. Whereas cytotoxic T lympho-
cyte  –  associated antigen-4 blockade has shown promising preclinical and clinical results, 
therapeutic CD4  +  CD25  +   T reg cell depletion has failed to consistently enhance immune-
based therapies. Using B16/BL6, a transplantable murine melanoma model, we show a 
dichotomy between the effects of T reg cell depletion on tumor rejection dependent on 
whether depletion occurs before (prophylactic) or after (therapeutic) tumor engraftment. 
Failure to promote rejection with therapeutic depletion is not related to lack of T reg cell 
depletion, to elimination of CD25  +   effector T cells, or to a failure to enhance systemic 
antitumor T cell responses, but correlates with failure of effector cells to infi  ltrate the 
tumor and increase the intratumor ratio of effector T cell/T reg cell. Finally, systemic 
antitumor responses generated upon therapeutic T reg cell depletion are signifi  cantly 
stronger than those generated in the presence of T reg cells, and are capable of eliciting 
rejection of established tumors after transfer into immunoablated recipients receiving 
combination immunotherapy. The data demonstrate a dissociation between measurable 
systemic responses and tumor rejection during CD25-directed T reg cell depletion, 
and suggest an alternative, clinically applicable strategy for the treatment of 
established tumors. 
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despite the generation of signifi  cant systemic antitumor reac-
tivity. Finally, our study provides evidence suggesting that 
the enhancement of systemic antimelanoma reactivity after 
therapeutic T reg cell depletion before vaccination might be 
exploited in the context of adoptive therapy after nonmye-
loablative conditioning. 
    RESULTS   
  Therapeutic CD25  +   depletion fails to synergize 
with Gvax/    CTLA-4 in rejection of established B16/BL6 
melanoma tumors 
  We previously showed that the strong antitumor eff  ect of 
Gvax/    CTLA-4 varied depending on the time of treatment, 
and that its effi   ciency was reduced when used more than 4 d 
after implantation of the B16/BL6 melanoma cell line (  21  ). 
To determine whether CD25-directed depletion of T reg 
cells could be used to boost the antitumor eff  ect of Gvax/
    CTLA-4, we deferred the combination vaccination therapy 
until 8 d after tumor implantation, a time point at which 
Gvax/    CTLA-4 is incapable of rejecting tumors. In the con-
text of this delayed therapy (Gvax/    CTLA-4 treatment at 8, 
11, and 14 d after implantation), we depleted CD25  +   cells 
either before (  “  prophylactic  ”  ) or after (  “  therapeutic  ”  ) tumor 
establishment (  Fig. 1 A  ).   Time points for anti-CD25 admin-
istration where chosen based on data showing that effi   cient 
depletion of CD4  +  CD25  +   T reg cell has occurred by 4 d 
after mAb injection (  Fig. 1 B  ). As expected, in the absence of 
CD25 depletion, Gvax/    CTLA-4 failed to induce rejection 
of B16/BL6 melanoma tumors (  Fig. 1 C  ). Although prophy-
lactic CD25 depletion and Gvax/    CTLA-4 synergized to 
reject established tumors, therapeutic CD25 depletion had 
no impact on tumor growth and rejection (  Fig. 1 C  ). 
  Both prophylactic and therapeutic CD25 depletion prevent 
Gvax/    CTLA-4  –  induced T reg cell accumulation 
  To understand the lack of synergy in the therapeutic setting, 
we fi  rst analyzed the percentage and number of CD4  +  Foxp3  +   
cells in LNs 14 d after tumor challenge. Prophylactic or thera-
peutic CD25 depletion induced a signifi  cant reduction in the 
percentage of CD4  +  Foxp3  +   cells independently of Gvax or 
Gvax/    CTLA-4 (P   <   0.05;   Fig. 2 A  ).   Interestingly, Gvax and 
Gvax/    CTLA-4 resulted in an increase in the absolute num-
ber of T reg cells over that of nonvaccinated mice (P   <   0.05; 
  Fig. 2 B  ). Although anti-CD25 reduced the number of 
CD4  +  Foxp3  +   T cells in nonvaccinated mice, the most strik-
ing diff  erence was observed in mice that had also been vacci-
nated with Gvax or Gvax/    CTLA-4, where anti-CD25 
prevented the accumulation of CD4  +  Foxp3  +   T reg cells re-
gardless of the timing of depletion (P   <   0.001). Analyses for 
expression of  the  proliferation marker KI-67 showed that 
Gvax or Gvax/    CTLA-4 induced a relatively modest increase 
in the percentage of KI-67  +  CD4  +  Foxp3  +   cells, that anti-CD25 
resulted in a signifi  cant increase in the KI-67  +   population, 
and that the greatest increase was induced by the combination 
of anti-CD25 and Gvax or Gvax/    CTLA-4, independent 
of the timing of anti-CD25 administration (P   <   0.01;   Fig. 2 C  ). 
that anti-CD25 antibodies also target and deplete CD25  +   
eff  ector T cells, thus eliminating antitumor eff  ectors either as 
they are generated or upon antigen encounter within the 
tumor. Alternative possibilities are that CD25-directed ther-
apy fails to deplete intratumoral CD25  +   T reg cells, or that 
persistence of CD25      /low  Foxp3  +   T cells or conversion of 
CD4  +  Foxp3        into CD4  +  Foxp3  +   is suffi   cient to prevent ef-
fective antitumor responses (  16, 17  ). Despite these issues, 
CD25-directed T reg cell depletion has proceeded to clinical 
application in the form of LMB-2 (a CD25-directed immuno-
toxin) (  18  ) and denileukin diftitox, or ONTAK (recombi-
nant IL-2 fused to diphtheria toxin [DT]). Clinical data suggest 
that ONTAK decreases the number of CD4  +  CD25  +  Foxp3  +   
T reg cells and heightens antitumor T cell responses as mea-
sured in the blood of patients with renal cell carcinoma and 
metastatic melanoma (  19, 20  ). Interestingly, none of these 
studies documented signifi  cant clinical responses, suggesting 
a disparity between measurable systemic responses and objec-
tive clinical responses. 
  In view of these data, and to inform the rational develop-
ment of clinical strategies incorporating T reg cell depletion, 
it becomes essential to understand the impact of depletion on 
antitumor immune responses and to clarify the parameters 
that determine therapeutic activity and resistance. In addi-
tion, it is germane to determine whether combinatorial ap-
proaches, including other immunostimulatory components, 
accomplish rejection of established tumors. GM-CSF  –  secret-
ing cellular vaccines (Gvax) and blocking anti  –  cytotoxic T 
lymphocyte  –  associated antigen-4 (CTLA-4) antibodies have 
been convincingly shown to synergize in mouse tumor 
models, including the poorly immunogenic B16/BL6 mela-
noma (  21, 22  ), and both have entered clinical trials (  23  –  29  ). 
Whereas Gvax promotes dendritic cell maturation, improv-
ing tumor antigen presentation and T cell activation (  30, 31  ), 
CTLA-4 (a transmembrane receptor that is expressed on ac-
tivated and regulatory T cells) can negatively modulate T cell 
activation in a cell intrinsic manner (  32  –  34  ). CTLA-4 in-
hibits antitumor T cell responses occurring in vivo as indi-
cated by the enhanced immunity and tumor rejection induced 
by CTLA-4 blockade (  35  ). Using a model for established 
mouse B16/BL6 melanoma, we combined Gvax/CTLA-4 
blockade with prophylactic versus therapeutic CD25-di-
rected depletion and studied their eff  ects on systemic and lo-
cal antitumor immunity. Our data indicate that depletion of 
T reg cells after tumor establishment results in a dissociation 
between systemic immunity and objective clinical responses. 
This directly correlated both with lack of accumulation of ef-
fector T cells within the tumor and a lack of activation of the 
intratumoral vasculature, but not with systemic depletion of 
CD25  +   eff  ector T cells. Thus, contrary to current opinion, 
our data suggest that neither concurrent depletion of eff  ector 
T cell nor incomplete depletion of T reg cells limit the thera-
peutic effi   cacy of CD25-directed approaches in enhancing 
antitumor responses. Furthermore, our data suggest that the 
therapeutic activity of T reg cell depletion may primarily be 
limited by failure to promote intratumoral T cell infi  ltration, JEM VOL. 205, September 1, 2008 
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tion 14 d after tumor challenge to determine whether the lack 
of synergy between therapeutic CD25-depletion and Gvax/
    CTLA-4 could be explained by depletion of CD25  +   eff  ector 
T cells. In LNs from untreated mice, the Foxp3  +   compart-
ment showed higher expression of KI-67 (16.6%) than the 
Foxp3       CD4  +   (4%) or CD8  +   T compartments (7.2%;   Fig. 3 A  ).   
Gvax/    CTLA-4 treatment caused increased KI-67 expression 
in all compartments, with the biggest increase (more than 
Collectively, the data suggest that therapeutic intervention with 
Gvax or, moreover, with Gvax/    CTLA-4 (after tumor implan-
tation) induces accumulation of T reg cells, and that although 
anti-CD25 effi   ciently limits their accumulation, a large pro-
portion of the surviving T reg cell population enters cell cycle 
in response to this combination of treatments. 
  Both prophylactic and therapeutic CD25 depletion promote 
strong systemic antitumor T cell reactivity 
  We next analyzed systemic anti-B16/BL6 melanoma re-
sponses by assessing T cell proliferation and cytokine produc-
    Figure 1.     Therapeutic CD25  +   depletion fails to synergize with 
Gvax/    CTLA-4 in rejection of established tumors.   (A)    Mice were in-
jected with anti-CD25 mAb 4 d before or after challenge with B16/BL6, 
and then treated with Gvax/    CTLA-4 on days 8, 11, and 14. (B) Represen-
tative plot for the expression of CD25 and Foxp3  +   by the CD4  +   T cell com-
partment 4 d after treatment with 400   μ  g of anti-CD25 mAb. (C) Tumor 
growth was monitored over time for mice treated with Gvax/   CTLA-4 
(black squares;   n   = 10), anti-CD25 d-4 and Gvax/    CTLA-4 (blue triangles; 
  n   = 10), and anti-CD25 d+4 plus Gvax/    CTLA-4 (inverted red triangles; 
  n   = 10). Data are representative of 3 independent experiments (  n   =  10 
mice per group in all experiments).     
    Figure 2.     CD25 depletion prevents Gvax/    CTLA-4  –  induced T reg 
cell accumulation.   Mice were injected with anti-CD25 mAb 4 d before or 
after challenge with B16/BL6, and then treated or not with Gvax or Gvax/
    CTLA-4 on days 8 and 11, as shown in   Fig. 1 A  . LNs were analyzed for 
expression of CD4, Foxp3  +  , and KI-67 14 d after tumor challenge. Data in 
A represent the percentage of CD4  + Foxp3 +   cells obtained from individual 
mice. (B) The percentage of CD4  + Foxp3 +   T cells was multiplied by the total 
number of lymphocytes to calculate the absolute number of CD4  + Foxp3 +  
T reg cells. Data in C represent the percentage of KI-67  +   cells within the 
CD4  + Foxp3 +   compartment. Closed circles represent no depletion, and 
open circles represent CD25 depletion. Data are representative of 3 inde-
pendent experiments (  n   = 3 mice per group).     2128 T REG CELL DEPLETION AND CTLA-4 BLOCKADE IN TUMOR REJECTION   | Quezada et al. 
    Figure 3.     CD25 depletion promotes strong peripheral antitumor T cell reactivity.   Mice were challenged with B16/BL6 melanoma and either left 
untreated or treated with Gvax/    CTLA-4 on days 8 and 11 after tumor implantation. Some groups also received anti-CD25 mAb 4 d before or after tumor 
challenge. (A) 14 d after tumor challenge, mice were analyzed for the expression of KI-67 within the CD4  + Foxp3     ,  CD8 +  , or CD4  + Foxp3 +   T cell compart-
ments. (B) Mice were injected with congenically marked pmel Tg CD8  +   T cells, treated as described in A, and analyzed for KI-67 expression on the pmel 
compartment 14 d after tumor challenge. Numbers on the top right of the histograms represent the percentage of cells expressing high levels of KI-67. 
(C – E)  CD8 +   and CD4  +   T cells were purifi  ed from each experimental group described in A and restimulated in vitro with a mix of purifi  ed CD11c  +   dendritic 
cells and irradiated B16 melanoma or control TRAMP-C2 tumor cell lines for 24 h. Production of IFN-     by  CD8 +   (C) and CD4  +   (D), and the production of 
IL-2 by CD4  +   T cells (E), was determined as described in the Materials and methods. (A  –  C) Data are representative of 3 independent experiments (  n   =  3 
mice per group).     JEM VOL. 205, September 1, 2008 
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threefold) in CD4  +  Foxp3        cells (  Fig. 3 A  ). Anti-CD25 syn-
ergized with Gvax/    CTLA-4 to further increase prolifera-
tion of CD4  +   and CD8  +   cells independently of the timing 
of administration (  Fig. 3 A  ). These data refl  ect the impact 
of CD25-depletion on the overall proliferative state of each 
T cell compartment, but do not address issues of specifi  c-
ity or functionality of the proliferating cells. To test these, 
we adoptively transferred melanoma (gp100)-reactive TCR 
transgenic CD8  +   (pmel) T cells (  36  ) into mice that were 
then treated as previously described (  Fig. 1 A  ). Upon tumor 
challenge, an increase in KI-67 expression was observed in 
tumor-reactive pmel Tg cells (  Fig. 3 B  ). Gvax/    CTLA-4 in-
duced higher KI-67 expression compared with naive and 
untreated mice, whereas CD25 depletion further increased 
T cell proliferation independently of the timing of depletion 
(  Fig. 3 B  ), following a trend similar to that observed for the 
CD8  +   polyclonal compartment (  Fig. 3 B  ). To assess function-
ality of the eff  ector T cell compartment, CD8  +   and CD4  +   T 
cells were purifi  ed and tested for IFN-     and IL-2 production 
in response to the B16/BL6 melanoma cell line. No IFN-     
production by T cells was detected in untreated mice, whereas 
Gvax/    CTLA-4 caused a small but signifi  cant increase in its 
production by both CD8  +   and CD4  +   T cells (P   <   0.05;   Fig. 3, 
C and D  ). Prophylactic CD25 depletion further increased 
IFN-     secretion (P   <   0.01;   Fig. 3, C and D  ). Rather than 
reducing IFN-     production, therapeutic CD25-depletion 
caused an additional signifi  cant increase (P   <   0.05;   Fig. 3 C  ), 
which was most marked in the CD4  +   compartment (P   <   
0.001;   Fig. 3 D  ). A similar trend was observed for IL-2, 
where therapeutic CD25-depletion led to a large increase in 
its production by CD4  +   T cells (P   <   0.001;   Fig. 3 E  ). The lack 
of depletion of activated eff  ectors by therapeutic anti-CD25 
was further corroborated by enumeration of IFN-      –  produc-
ing CD4  +   and CD8  +   T cells by ELISPOT analyses (not de-
picted), as well as by analysis of absolute numbers of KI67  +   
eff  ector T cells (CD4  +  , CD8  +  , and pmel; Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20080099/DC1). 
Together, these data strongly suggest that prophylactic and 
therapeutic CD25 depletion does not result in elimination of 
eff  ector T cells, but promotes strong systemic T cell responses 
against B16/BL6 melanoma. 
  Therapeutic Foxp3  +  -directed T reg cell depletion fails 
to synergize with Gvax/    CTLA-4 in rejection of established 
B16/BL6 melanoma tumors 
  To confi  rm that the lack of effi   cacy of therapeutic CD25 
depletion was independent of depletion of CD25  +   eff  ector 
T cells, and to further exclude the possibility that residual 
CD25      /low  Foxp3  +   cells that escaped depletion by anti-CD25 
(  Fig. 1 B  ) were signifi  cant in preventing tumor rejection, we 
used Foxp3-DTR transgenic mice as tumor recipients. These 
mice express the primate DT receptor under the control of 
the mouse Foxp3  +   promoter, and upon DT injection, most 
Foxp3  +   cells are rapidly eliminated. In contrast to CD25-directed 
depletion (  Fig. 1 B  ), this approach depletes CD25      /low  Foxp3  +   
T cells (  Fig. 4 B  ) and is not complicated by the possibility of 
CD25  +   eff  ector T cell depletion, as these cells do not ex-
press Foxp3 in mice.   Similar to the results we observed with 
anti-CD25, Foxp3  +  -directed depletion before challenge with 
B16/BL6 melanoma (  Fig. 4 A  ) resulted in effi   cient tumor 
rejection, whereas late depletion failed to synergize with 
Gvax/    CTLA-4 (  Fig. 4 C  ). Together with the data shown 
in   Fig. 3  , these data suggest that therapeutic CD25 depletion 
does not impair peripheral antitumor responses, but that it 
effi   ciently synergizes with Gvax/    CTLA-4 to induce further 
    Figure 4.     Therapeutic Foxp3-directed T reg cell depletion fails to 
synergize with Gvax/    CTLA-4 in rejection of established tumors.  
(A) Foxp3-DTR transgenic mice or littermate WT control were injected with 
900 ng of DT on days     1 and 0 or 8 and 9, challenged with B16/BL6 at day 0, 
and treated with Gvax/anti  –  CTLA-4 on days 8, 11, and 14. (B) Representa-
tive plot for the expression of CD25 and Foxp3  +   by the CD4  +   T cell compart-
ment on days 2 and 4 after DT injection. (C) Tumor growth was monitored 
over time in Foxp3-DTR or littermate mice challenged with B16 melanoma 
and treated with Gvax/    CTLA-4 on days 8, 11, and 14. Foxp3-DTR mice 
were also treated with DT early (blue triangles;   n   = 10) or late (red squares; 
  n   = 10), as described in A. Littermate controls were also treated with DT 
early (black triangle;   n   = 10) or late (black square;   n   = 10). Data are repre-
sentative of 3 independent experiments (  n   = 10 mice per group).     2130 T REG CELL DEPLETION AND CTLA-4 BLOCKADE IN TUMOR REJECTION   | Quezada et al. 
pletion had an additive eff  ect, inducing the proliferation of 
the whole intratumor eff  ector T cell compartment regardless 
of the timing of anti-CD25 administration. Interestingly, al-
though proliferation of the eff  ector T cell compartment de-
pended on treatment (Gvax/    CTLA-4 or CD25 depletion), 
Foxp3  +   T reg cells appeared to stay in the cell cycle, suggest-
ing a constant turnover within the tumor (  Fig. 5  ). Increased 
proliferation of intratumoral eff  ector T cells could be attrib-
uted to an overall reduction in the number, and hence local 
suppressive capacity, of T reg cell in the tumor, but could 
also result from systemic T reg cell depletion and migration 
of proliferating eff  ector T cells into the tumor. These mecha-
nisms are not mutually exclusive. 
  These data reveal the independent contributions of Gvax/
    CTLA-4 and CD25 depletion to the expansion of the intra-
tumor eff  ector T cell compartment, but do not explain the lack 
of synergy between Gvax/    CLTA-4 and therapeutic CD25-
depletion on tumor rejection because the eff  ects on prolifera-
tion were similar regardless of the timing of anti-CD25. 
  Effi  cient tumor infi  ltration and augmentation 
of the intratumor effector T cell/T reg cell ratio depends 
on timing of anti-CD25 administration 
  To further investigate the impact of treatment on intra-
tumoral immune responses, we quantifi  ed T cell infi  ltration, 
proliferation and activity of tumor-reactive T cells. Whereas 
the synergy observed with Gvax/    CTLA-4 and prophylactic 
Foxp3-directed depletion supports the validity of this de-
pletion model, the lack of synergy in the therapeutic Foxp3-
directed T reg cell depletion supports the data in   Fig. 1 C   
and further suggests that failure does not result from the ef-
fects of a pool of CD25      /low  Foxp3  +   cells escaping CD25-di-
rected depletion. 
  Gvax/    CTLA-4 and CD25 depletion differentially impact 
intratumor T cell proliferation 
  Given that therapeutic CD25 depletion promoted strong sys-
temic antitumor responses but, in contrast to prophylactic 
depletion, failed to induce rejection of B16/BL6 melanoma 
tumors, we asked whether local diff  erences within the tumor 
might be impacting outcomes. We therefore focused on in-
tratumor responses 14 d after tumor challenge, and evaluated 
expression of KI-67 by the eff  ector T cell (CD4  +  Foxp3        and 
CD8  +   T cells) and T reg cell (CD4  +  Foxp3  +  ) compartments 
(  Fig. 5  ).   Approximately 33% of eff  ector T cells isolated from 
untreated tumors expressed KI-67 compared with   >  70% of 
CD4  +  Foxp3  +   T reg cells. CD25 depletion drove mainly CD8  +   
T cells into the cell cycle, whereas Gvax/    CTLA-4 without 
CD25 depletion induced mainly CD4  +  Foxp3        T cells to pro-
liferate. The combination of Gvax/    CTLA-4 and CD25 de-
    Figure 5.     Gvax/    CTLA-4 and CD25 depletion differentially impact intratumor T cell proliferation.   Mice injected with anti-CD25 mAb 4 d before 
or after challenge with B16/BL6 were either left untreated or treated with Gvax/    CTLA-4 on days 8 and 11. 14 d after tumor challenge, tumors were iso-
lated and analyzed for expression of KI-67 within the CD4  + Foxp3     ,  CD8 +  , or CD4  + Foxp3 +   T cell compartments. As a comparison, KI-67 profi  les from LNs of 
naive mice are also shown. Numbers on the top right of the histograms represent the percentage of cells expressing high levels of KI-67. Data are repre-
sentative of 3 independent experiments (  n   = 3 mice per group).     JEM VOL. 205, September 1, 2008 
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Gvax/    CTLA-4, effi   ciently promoting accumulation of CD4  +   
and CD8  +   eff  ector T cells within the tumor, but only when 
administered before tumor challenge (  Fig. 6 A  ). Quantifi  -
cation of tumor infi  ltrates correlated with the histological 
analyses and with tumor rejection outcomes (  Fig. 1 C  ), dem-
onstrating that although prophylactic CD25-directed deple-
tion increased the intratumor ratio of CD8  +   eff  ector T cells/T 
reg cells (  Fig. 6 B  ), therapeutic depletion failed to increase 
the absolute number of CD8  +   eff  ector T cells in the tumor 
(  Fig. 6 C  ) or to switch the intratumor balance between eff  ec-
tors and regulators (  Fig. 6 B  ). Similar results were obtained 
and the ratio of eff  ector T cell/T reg cell, which has been 
shown to correlate with tumor rejection in mice (  9  ) and hu-
mans (  37, 38  ). Histological analysis of day 14 B16/BL6 tu-
mors from untreated mice revealed minimal T cell infi  ltration 
(  Fig. 6 A  ).   Whereas we previously demonstrated that thera-
peutic intervention at day 3 with Gvax/    CTLA-4 promoted 
signifi  cant intratumor accumulation of eff  ector T cells (  9  ), 
late intervention at day 8 failed to induce a similar eff  ect (  Fig. 
6 A  ) or to increase the intratumor ratio of eff  ector T cell/T 
reg cell (  Fig. 6 B  ), explaining the lack of rejection in this 
more established tumor model. Anti-CD25 synergized with 
    Figure 6.     Effi  cient tumor infi  ltration and augmentation of the intratumor effector T cell/T reg cell ratio depends on timing of anti-CD25 
administration.   Mice challenged with B16/BL6 tumor cells were either left untreated or received anti-CD25 mAb 4 d before or after tumor challenge, 
plus Gvax/    CTLA-4 on days 8 and 11 and then killed 14 d after challenge. (A) Analysis of frozen tumor sections by confocal microscopy. Anti – CD8-Alexa-
488 (green), anti-CD31 PE (red), and anti-CD11c APC (blue) are shown in the top row. Anti  –  CD4-Alexa-488 (green), anti-CD31 PE (red), and anti-Foxp3 
(blue) are shown in the bottom row. Bar, 40   μ  m. (B, C, and D) In parallel experiments, tumors were harvested, processed for enrichment of TILs, and ana-
lyzed by fl  ow cytometry for the expression of CD8, Foxp3, and CD45.1 (pmel transgenic cells). Tumors were pooled for each group, and data show the 
ratio of CD8  +   cells to Foxp3  +   cells  infi  ltrating the tumors (B), the number of total CD8  +   cells per gram of tumor (C), and the number of CD8  +   pmel  trans-
genic cells per gram of tumor (D). In E, mice were treated as described in A and analyzed for the expression of ICAM (green), CD31 (red), and VCAM (blue) 
within the tumors 14 d after challenge. Bar, 40   μ  m. All images were acquired with a 20  ×   water immersion objective. Data are representative of 3 indepen-
dent experiments (  n   = 3 mice per group).     2132 T REG CELL DEPLETION AND CTLA-4 BLOCKADE IN TUMOR REJECTION   | Quezada et al. 
  Radiation therapy and CD25-depleted adoptive cell transfer 
synergize with Gvax/    CTLA-4 to reject established B16/BL6 
melanoma tumors 
  Despite failing to induce infi  ltration and tumor rejection, thera-
peutic CD25 depletion signifi  cantly potentiates the systemic 
activation of eff  ector T cells induced by Gvax/    CTLA-4 
(  Fig. 3 ). Although the enhancement in activation is clearly shown 
at the levels of proliferation, accumulation, and IL-2 and 
IFN-     production, we wanted to further determine if this 
reactivity was capable of inducing tumor rejection in vivo. 
We therefore compared their capacity to reject established tu-
mors upon transfer into conditioned hosts. We hypothesized 
that if the responses generated through therapeutic T reg cell 
depletion were stronger than those generated in nondepleted 
donors, they could be exploited and used for adoptive cell 
therapy after nonmyeloablative host conditioning, particularly 
because such combinatorial strategies have been reported to 
render some tumors, including B16 melanoma, more accessi-
ble to T cell infi  ltration (  43, 44  ). Donor lymphocyte infusions 
(DLIs) were generated from B16/BL6 tumor-bearing mice 
treated with Gvax/    CTLA-4 with or without therapeutic 
anti-CD25 (Fig. S3 A, available at http://www.jem.org/cgi/
content/full/jem.20080099/DC1), and administered 8 h af-
ter irradiation of recipient mice bearing 8-d-old B16/BL6 tu-
mors. Recipients were then treated with Gvax/    CTLA-4 to 
further activate the DLI in vivo because irradiation followed 
by DLI alone showed no impact on tumor growth in pre-
liminary experiments (unpublished data). Irradiation induced 
a signifi  cant reduction in the absolute number of CD8  +   (  Fig. 
8 A  ) and Foxp3  +   T cells (  Fig. 8 B  ).   The impact was greater 
on the CD8 compartment, resulting in a decrease in the ef-
fector T cell/T reg cell ratio (  Fig. 8 C  ). DLI induced a com-
parable enhancement in CD8  +   T cell recovery independent 
of donor CD25-depletion (  Fig. 8 A  ) without a signifi  cant 
impact on absolute Foxp3  +   T cell numbers (  Fig. 8 B  ), lead-
ing to recovery of the eff  ector T cell/T reg cell ratio (  Fig. 
8 C  ). Although donor CD25 depletion did not contribute 
after the transfer of transgenic tumor-specifi  c pmel cells into 
mice before treatment (  Fig. 6 D  ). 
  Together, our data show that therapeutic CD25-directed 
depletion induces strong systemic antitumor responses, but 
that tumor-reactive T cells fail to infi  ltrate or accumulate 
in the tumor unless CD25  +   T reg cells are eliminated be-
fore tumor establishment. We believe these are the fi  rst data 
informing an explanation for the discrepancies between sys-
temic antitumor responses and lack of tumor rejection af-
ter therapeutic CD25-directed depletion observed in the 
clinical setting (  19, 20  ). Several studies suggest that tumor 
vasculature may diff  er from regular vasculature upon tumor 
establishment (  39  –  41  ). This altered or abnormal vasculature 
may be less permeable to activated T cells, in part because 
of its inability to up-regulate adhesion molecules such as in-
tercellular adhesion molecule (ICAM) and vascular adhesion 
molecules (VCAM) (  42, 43  ). Therefore, we next focused on 
the possibility that diff  erences in vascular activation may cor-
relate with our observations, and evaluated activation of the 
tumor vasculature by confocal immunofl  uorescent analysis 
of VCAM, ICAM, and CD31 expression. Only prophylactic 
CD25-directed depletion resulted in coexpression of these 
three markers (  Fig. 6 E  ). This correlated with intratumor 
T cell accumulation (  Fig. 6 A  ) and tumor rejection (  Fig. 
1 C  ), although, interestingly, the fi  nding that the tumor 
vasculature expresses low levels of ICAM and VCAM unless 
T reg cells are prophylactically depleted remains a correla-
tive observation at this time. Further data suggest that ac-
tivation of the tumor vasculature is not necessarily linked 
directly to T reg cell depletion. In brief, we have previously 
shown that early therapy with Gvax/anti  –  CTLA-4 (3 d after 
challenge with B16/BL6 tumors instead of 8 d) induces ef-
fi  cient tumor rejection, and that rejection correlates with an 
increase in the intratumor ratio of CD8  +   eff  ector T cells to 
CD4  +  Foxp3  +   cells (  9  ). Analyses of these rejecting tumors re-
veals increased expression of ICAM and VCAM by the tumor 
vasculature, providing support for the idea that expression 
of these molecules strongly correlates with infi  ltration and 
tumor rejection, even in the absence of T reg cell depletion 
(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20080099/DC1). We therefore believe that the diff  er-
ences in endothelial activation marker expression may result 
from several contributing factors and do not primarily refl  ect 
a direct infl  uence of T reg cell on the tumor vasculature. 
Finally, in the absence of Gvax/    CTLA-4, prophylactic, but 
not therapeutic, CD25-directed depletion results in a small 
but signifi  cant CD8  +   T cell infi  ltrate within the tumor, to-
gether with a variable but signifi  cant increase in the intratu-
mor eff  ector T cell/T reg cell ratio ( Fig. 7, A and B ), although 
this is not suffi   cient to induce clear changes in vascular acti-
vation or tumor rejection (not depicted).    This early altera-
tion of intratumor T cell infi  ltration may have signifi  cance in 
the subsequent synergy with delayed Gvax/CTLA-4 block-
ade, perhaps shifting the balance of eff  ectors to suppressors 
suffi   ciently to allow the combination vaccination strategy to 
become eff  ective. 
    Figure 7.     CD25 depletion before tumor challenge promotes partial 
tumor infi  ltration in the absence of Gvax/    CTLA-4.   Mice were chal-
lenged with B16/BL6 melanoma tumor cells and treated or not treated 
with anti-CD25 mAb 4 d before or after tumor challenge. 14 d after tu-
mor implantation, tumors were harvested and analyzed for the expression 
of CD8 and Foxp3 by fl  ow cytometry (A) or CD8 (green) and CD31 (red) by 
confocal microscopy (B). Bar, 100   μ  m.     JEM VOL. 205, September 1, 2008 
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irradiation alone (not depicted), no expression was detected 
in the absence of T cell transfer 8 d after radiation therapy 
(  Fig. 8 E  ). Signifi  cant expression of ICAM and VCAM was 
only observed upon irradiation and T cell transfer (  Fig. 8 E  ), 
suggesting that infi  ltrating T cells are, at least in part, an im-
portant factor in further increasing vasculature activation, which 
might then result in enhanced T cell infi  ltration (  Fig. 8 E  ) 
to recovery of T cell numbers, it signifi  cantly increased ef-
fector function measured as IFN-     production by CD8  +   ef-
fector T cells in response to B16/BL6 (  Fig. 8 D  ). This last 
observation could be attributed, at least in part, to the di-
minished frequency of T reg cells present in the DLIs from 
CD25-depleted donors (Fig. S3 B). Interestingly, although a 
small increase in ICAM expression was observed 24 h after 
    Figure 8.     Radiation therapy and CD25-depleted adoptive cell transfer synergize with Gvax/    CTLA-4 to reject established tumors.  To  gener-
ate the DLIs, tumor-bearing mice were injected or not injected with anti-CD25 on day 4 after challenge with B16/BL6 melanoma, and then treated with 
Gvax/    CTLA-4 on days 8, 11, and 14. 19 d after tumor challenge, T cells were isolated from donor mice and injected into mice bearing 8-d-old tumors. 
All mice receiving DLI were also treated with radiation therapy (RT) 8 h before the DLI. (A  –  E) Recipient mice were killed 18 d after tumor challenge. 
(A  –  C) Spleens were analyzed for expression of CD8, CD4, and Foxp3 using fl  ow cytometry. All recipient mice were treated with Gvax/    CTLA-4 as described 
in the Materials and methods section. The groups were as follow: no RT no DLI (recipients receiving only Gvax/    CTLA-4 without RT or DLI), +RT no DLI 
(recipients receiving RT without DLI and then Gvax/    CTLA-4), +RT+DLI (recipients receiving RT, DLI, and Gvax/    CTLA-4), and +RT+DLI (   CD25)  (recipients 
receiving RT, DLI from CD25-depleted donors, and Gvax/    CTLA-4). The data are presented as number of CD8  +   cells (A), number of CD4  + Foxp3 +   T cells (B), 
and ratio of CD8  +   T cells to CD4  + Foxp3 +   T cells (C). In D, CD8  +   T cells were purifi  ed from the different groups and restimulated in vitro with irradiated B16 
melanoma or control TRAMP-C2 tumor cell lines for 24 h. IFN-     production was determined by ELISPOT assay, as described in the Materials and methods 
section. (E) Tumors were harvested from mice in the different groups, and frozen sections were stained with anti-VCAM FITC (green), anti-CD31 PE (red), 
and anti-ICAM APC (magenta) in the top row. The bottom row shows tumor sections stained with anti-CD8 Alexa Fluor 488 (green) and anti-CD31 PE 
(red). All images were acquired with a 20  ×   water immersion objective. Bar, 40   μ  m. (F and G) In a parallel set of experiments, tumor growth was followed 
over time. Whereas F shows tumor growth over time, G presents data as the percentage of mice surviving after tumor challenge and treatment. 
A  –  D shows cumulative data from 4 different experiments (  n   = 3 mice per group). In E, the data are representative of 4 independent experiments (  n   =  3 
mice per group), and F and G are representative of 3 independent experiments (  n   = 10 mice per group).     2134 T REG CELL DEPLETION AND CTLA-4 BLOCKADE IN TUMOR REJECTION   | Quezada et al. 
cient to infl  uence B16/BL6 tumor growth if administered in 
a   “  therapeutic  ”   setting. This failure was not caused by a lack 
of enhancement of systemic immunity, or by the persistence 
of CD25      /low  Foxp3  +   T cells, or by an inability to infl  uence 
the proliferation profi  les of intratumoral T cells; rather, it 
seemed to correlate with a lack of traffi   cking of activated ef-
fector T cells into the tumor that itself correlated with a lack 
of activation of the tumor vasculature. The demonstration 
that failure of CD25-directed therapy was unrelated to eff  ector 
T cell depletion has broader signifi  cance to other approaches 
targeting T reg cell number or function (  48  ), as illustrated 
by the similarity in outcomes after Foxp3-directed depletion 
(  Fig. 4 C  ). Its impact on the proliferative fraction of nodal 
T reg cells (  Fig. 2 C  ) highlights the potential for rapid re-
population of this compartment after therapeutic perturbation, 
either by de novo generation or by conversion of eff  ector T 
cell into Foxp3  +   T reg cells (  16  ). This also suggests that pro-
longed suppression of T reg cell numbers refl  ects a dynamic 
balance of ongoing depletion and repopulation. This has rele-
vance to the timing of individual elements of combinatorial 
strategies, particularly if the therapy targeting T reg cells is 
short-acting and the therapeutic window correspondingly nar-
row. Conversely, rapid repopulation may allow exploitation 
of a briefl  y more   “  immunoreceptive  ”   environment, but limit 
more widespread toxicities associated with heightened auto-
reactivity (  1  ). Inhibition of T reg cell function may provide 
an attractive alternative to depletion, avoiding the complications 
of homeostatic repopulation of the T reg cell compartment, 
although to date little is known about pathways specifi  cally 
required for T reg cell function, thus limiting the development 
of targeted therapeutics (  10  ). 
  Although therapeutic CD25-depletion resulted in a sig-
nifi  cant enhancement of the systemic CD4  +   and CD8  +   anti-
B16/BL6 melanoma T cell responses, these activated T cells 
failed to effi   ciently infi  ltrate the tumor and to increase the in-
tratumor ratio of eff  ector T cells/T reg cells (  Fig. 6, A and B  ). 
Several studies suggest that tumor vasculature may diff  er from 
regular vasculature upon tumor establishment (  39  –  41  ), and 
that this altered vasculature is less permeable to tumor-reac-
tive lymphocytes (  42  ). This could explain the dissociation 
between systemic and intratumor responses observed in this 
study, and is further supported by the correlation between 
lack of tumor infi  ltration and failure of the tumor vasculature 
to express the adhesion molecules ICAM and VCAM. Ex-
pression of ICAM and VCAM was observed only when T 
reg cells were depleted before tumor establishment (  Fig. 6 E  ) 
and correlated with T cell infi  ltration and rejection of B16/
BL6 melanoma tumors. Although this is an interesting pre-
liminary observation, the direct induction of ICAM and VCAM 
expression may not be mechanistically critical for initiation 
of rejection, but rather be amplifi  ed during the processes of 
infi  ltration and rejection. This is supported, at least in part, by 
data showing that B16/BL6 melanoma tumors treated at ear-
lier time points with Gvax/    CTLA-4 (at day 3 after implan-
tation in contrast to day 8), demonstrate similar up-regulation 
of ICAM and VCAM on the tumor vasculature, even in the 
and tumor rejection (  Fig. 8, F and G  ). Activation of intra-
tumoral vasculature and enhanced CD8  +   T cell accumulation 
occurred independently of whether the donor had received 
anti-CD25 (  Fig. 8 E  ). Importantly, however, we observed 
that although DLI from nondepleted mice led to delayed tu-
mor growth (  Fig. 8 F  ) and a signifi  cant increase in survival 
(  Fig. 8 G  ), a maximal eff  ect was obtained only with DLI from 
CD25-depleted donors (  Fig. 8  ). This greater protection di-
rectly correlated with the enhanced activity and frequency of 
tumor-reactive T cells generated by therapeutic depletion of 
T reg cells (  Fig. 3   and   Fig. 8 D  ), supporting the hypothesis 
that systemic responses during therapeutic T reg cell depletion 
are not diminished because of bystander elimination of eff  ector 
T cells. In addition to enhanced T cell activity, recruitment 
of high avidity tumor-reactive T cells has been shown after 
CD25- or cyclophosphamide-directed T reg cell depletion, 
and this could further help to explain the increased protection 
with the DLI from CD25-depleted donors ( 45  ). It is important 
to note that all components of this intervention appear essen-
tial for optimal antitumor responses because tumor rejection 
was not observed in preliminary experiments lacking condi-
tioning of the recipients, the DLI, or the Gvax/    CTLA-4 
booster vaccinations of the recipients (unpublished data). We 
believe that the apparent dependency on administration of 
Gvax/    CTLA-4 to the recipient after DLI most likely results 
from a requirement to further increase T cell numbers and 
reactivity against the tumor (Fig. S4). 
  Together, the data suggest that the systemic responses gen-
erated by Gvax/    CTLA-4 and therapeutic CD25 deple-
tion are stronger than those from nondepleted mice and 
that, in combination with host conditioning, they induce re-
jection of established melanoma tumors without further ex 
vivo manipulation. 
    DISCUSSION   
  Recent advances in immunostimulatory cancer therapies 
have restored faith in the idea that the immune system can 
be harnessed to achieve clinically meaningful antitumor re-
sponses. A plethora of potential targets are now available. Just 
as with conventional chemotherapeutics, it is likely that com-
binatorial, and possibly multimodal, strategies will prove to 
be the most eff  ective. Data addressing mechanisms of action 
and interaction can inform the rational development of such 
strategies and may be critical in expediting their application. 
We have focused on several of the most clinically advanced 
and immediately relevant approaches. Our data illustrating 
the accumulation of T reg cells in response to Gvax support 
the concept that many, if not all, direct immunostimulatory 
approaches (e.g., enhancing DC numbers, antigen-present-
ing capacity, or eff  ector T cell number or function) may be 
restricted by homeostatic inhibitory mechanisms, including 
the conversion and/or expansion of Foxp3  +   regulatory T 
cells (  16, 17, 46, 47  ). Blockade or removal of immune check-
points will likely be a valuable adjunct to enhance these ther-
apies (  10, 13  ). CD25-directed T reg cell depletion, although 
effi   ciently preventing T reg cell accumulation, was insuffi   -JEM VOL. 205, September 1, 2008 
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sis and given autologous DLI after nonablative therapy, with 
the advantage of transfer of a polyclonal product diminished 
in T reg cell numbers. Furthermore, the minimal ex vivo mani-
pulation obviates an increasing number of regulatory issues. 
Although direct application of such strategies to other human 
cancers may seem distant, similar approaches could be evalu-
ated in patients displaying heightened antitumor reactivity after 
immunotherapy, but failing to produce clinical responses. In 
these cases, systemic antitumor T cell responses could potentially 
be harnessed through apheresis before standard chemo- or 
radiotherapies, followed by reinfusion during the lymphope-
nic phase. Finally, our data allow refi  nement of a model illus-
trating the independent contributions of Gvax/    CTLA-4 and 
T reg cell depletion to systemic and intratumoral immune re-
sponses, helping to explain the dissociation of systemic and 
local immunity. Gvax/    CTLA-4 drives CD4  +   eff  ector T cell 
into the cell cycle, but also induces expansion of the T reg 
cell compartment in the periphery. Therapeutic CD25-tar-
geted T reg cell depletion controls the systemic accumulation 
of T reg cells, facilitating the activation of the CD4  +   and 
CD8  +   T cell compartments both systemically and within the 
tumor, but few activated T cells can access the tumor, at least in 
part because of abnormal tumor vasculature within established 
tumors, along with poor ICAM and VCAM expression. Re-
stricted infi  ltration results in a low eff  ector T cell/T reg cell 
ratio, which is insuffi   cient to elicit rejection of B16/BL6 mela-
noma. In contrast, prophylactic T reg cell depletion allows 
infi  ltration of modest numbers of CD8  +   T cells into the tu-
mor upon engraftment ( Fig. 7 ), which are suffi   cient to over-
come intratumoral resistance mechanisms after Gvax/    CTLA-4. 
The enhanced systemic immunity generated in response to 
therapeutic T reg cell depletion can be harnessed by transfer-
ring TRLs into tumor-bearing hosts after nonablative con-
ditioning, which results in effi   cient activation of the tumor 
vasculature, T cell infi  ltration, and rejection of established 
B16/BL6 melanoma. 
    MATERIALS AND METHODS   
  Mice.     C57BL/6 mice (6  –  8 wk old) were purchased from Taconic. 
C57BL/6 pmel TCR Transgenic mice that specifi  cally recognize a peptide 
derived from gp100 have been previously described (  36  ) and were pro-
vided by N. Restifo (National Cancer Institute, Bethesda, MD). C57BL/6 
Foxp3-DTR transgenic mice were generated in D. Littman  ’  s Laboratory 
at New York University School of Medicine (New York, NY). In brief, 
C57BL/6 blastocysts were microinjected with a modifi  ed 220-kb BAC 
containing a gene coding for the primate DTR under the control of 
the murine Foxp3 promoter. All cells expressing Foxp3  +   also express the 
DTR, and upon injection with Foxp3  +   cells are rapidly killed. All animals 
were maintained in microisolator cages and treated in accordance with the 
National Institutes of Health and American Association of Laboratory 
Animal Care regulations. All animal experiments were approved by the 
Memorial Sloan-Kettering Cancer Center Institutional Animal Care and 
Use Committee. 
  Antibodies.     Anti  –  CTLA-4 (clone 9H10) and anti-CD25 (clone PC61) 
were purchased from BioExpress and given i.p. for all in vivo studies. Anti-
KI-67 FITC was purchased from BD Biosciences and used according 
to manufacturer  ’  s instructions, whereas all other antibodies used for fl  ow 
cytometry were purchased from eBioscience. Anti-CD25 (clone 7D4) was 
absence of CD25-directed depletion (Fig. S2). Furthermore, 
the early activation of self-reactive T cells during prophy-
lactic T reg cell depletion may lead to infi  ltration of small 
numbers of CD8  +   cells into tumors (  Fig. 7  ), which might 
precede changes in vascular permeability that subsequently 
preclude effi   cient traffi   cking. This may be critical to effi   cacy 
in the prophylactic model compared with the therapeutic 
one, where T reg cell are depleted after tumor implantation, 
allowing the tumor suffi   cient time for generation of a less 
permissive microenvironment for infi  ltration. In the prophy-
lactic setting, the T cells infi  ltrating early after tumor chal-
lenge could contribute from within the tumor to enhance the 
eff  ects of Gvax/    CTLA-4, potentially infl  uencing vascular 
permeability and facilitating subsequent traffi   cking of the sys-
temic tumor-reactive pool. 
  To exploit the enhanced systemic immunity generated by 
vaccination after T reg cell depletion, and to further evaluate 
the antitumor activity of these cells, we purifi  ed T cells for 
transfer into B16/BL6 tumor-bearing recipients. The ability 
to use in vivo vaccine-primed autologous lymphocyte infu-
sions to enhance and direct immune reconstitution toward 
infectious pathogens after autologous hematopoietic stem cell 
transplantation (with additional posttransplant booster immu-
nizations) has been demonstrated in humans (  49  ). An exten-
sive literature on the use of tumor-infi  ltrating lymphocytes 
(TILs), expanded ex-vivo for infusion after lymphodepletion, 
informs the basis of our approach (  50  –  52  ). These studies sug-
gest that lymphodepletion eliminates cytokine sinks, as well 
as providing an environment that drives homeostatic prolif-
eration, and also demonstrates the importance of the trans-
ferred T reg cell population to the outcomes of adoptive 
cellular therapies (  53  ). In addition, and perhaps of great rele-
vance to overcoming the dissociation of systemic and local 
responses, host irradiation can sensitize the stromal cells sur-
rounding the tumor (  54  ) and induce up-regulation of adhe-
sion molecules on tumor vasculature that render the tumor 
susceptible to T cell infi  ltration (  43, 44  ). Finally, it has recently 
been shown that host irradiation releases LPS from com-
mensal gut microfl  ora, which further matures DCs and activate 
tumor-reactive T cells (  55  ). Although these approaches have 
shown early clinical potential in melanoma patients, the diffi   -
culty in isolation and expansion of TILs from these patients 
remains a limiting step in 60  –  70% of cases (  56  ). Alternative 
strategies for isolation of tumor-reactive lymphocytes (TRLs) 
would facilitate more widespread application (  57  ). Our data 
suggest a mechanism to take advantage of TRLs expanded 
in vivo. All elements (prevaccination of donor, irradiation, DLIs, 
and postinfusion booster vaccinations) were vital for effi   cacy 
in this preclinical model, which was maximized by therapeu-
tic T reg cell depletion of the donor (  Fig. 8  ). We observed 
rapid reconstitution of the T cell compartment, restoration 
of a more favorable eff  ector T cell/T reg cell ratio, genera-
tion of systemic antitumor responses, activation of the tumor 
vasculature, and effi   cient rejection of established B16/BL6 
melanoma tumors. The approach is potentially applicable to 
melanoma patients who have been vaccinated before aphere-2136 T REG CELL DEPLETION AND CTLA-4 BLOCKADE IN TUMOR REJECTION   | Quezada et al. 
eff  ector T cells/T reg cells and number of CD8  +   cells/gram of tumor were 
determined as previously described (  9  ). 
  Histology and confocal microscopy.     For confocal analysis, tumors were 
dissected and snap frozen in optimal cutting temperature solution. 8-    m 
sections were cut from frozen tumors using a cryomicrotome, and then fi  xed 
in cold acetone for 10 min and stained with anti-CD4 Alexa Fluor 488, anti-
CD8 Alexa Fluor 488, anti-Foxp3  +   APC, anti-CD31 PE, anti-CD11c APC, 
anti-ICAM FITC, and/or anti-VCAM APC. Samples were analyzed with 
an inverted confocal microscope (LSM; Leica) with a 20  ×   water immer-
sion objective. 
  Adoptive cell therapy experiments.     For adoptive cell therapy, we fol-
lowed the protocol described in Fig. S3 A. In brief, to generate T cells for 
the DLIs, all donor mice were challenged with 20,000 B16/BL6 tumor cells 
in the fl  ank and treated with Gvax and anti  –  CTLA-4 on days 8, 11, and 14. 
Half of the mice were also injected with 400   μ  g of anti-CD25 on day 4 after 
tumor challenge to generate a DLI from T reg cell  –  depleted donors (DLI 
CD25       ). 19 d after tumor challenge, donor mice were killed and T cells 
were purifi  ed from LNs and spleen using a pan  –  T cell purifi  cation kit from 
Miltenyi Biotech. 15   ×   10  6   T cells (  >  95% purity) from CD25-depleted (DLI 
CD25       ) or undepleted (DLI) donors were injected i.v. into mice bearing 
8-d-old tumors (from a 20,000-B16/BL6 challenge) that underwent radiation 
therapy (4.5 Gy) 8 h before cell transfer. All mice were treated with Gvax on 
days 9, 12, 15, and 18 and anti  –  CTLA-4 on days 9, 12, 15, 18, 21, and 24, 
and tumor growth was followed over time. For phenotypic, functional, and 
histological analyses, mice were killed 18 d after tumor challenge and the 
expression of CD4, CD8, CD25, and Foxp3  +  , as well as IFN-     production 
(ELISPOT), were studied as previously described in this section. 
  Statistical analysis.     Experimental group size was   n   = 3  –  5 for functional 
analysis and   n   = 10 for tumor growth experiments. Experiments were re-
peated two to three times, and the data were analyzed by one-way analysis 
of variance using the Bonferroni post-test correction for analysis between 
groups. P values   <  0.05 were considered statistically signifi  cant. Data for tu-
mor rejection was analyzed with Fisher  ’  s exact test, and P values   <  0.05 were 
considered statistically signifi  cant. 
  Online supplemental material.     Fig. S1 shows that therapeutic T reg 
cell depletion does not result in a decrease in the absolute number of ef-
fector T cells (KI67  +   or KI67       ). In Fig. S2, early intervention with Gvax/
anti  –  CTLA-4 (in the absence of T reg cell depletion) results in an increase 
in the expression of ICAM and VCAM on the tumor vasculature. Fig. S3 
outlines the in vivo protocol for the DLI experiments. In Fig. S4, the 
combination of Gvax and anti  –  CTLA-4 treatment results in maximal T 
cell responses in the adoptive cell transfer experiments. The online ver-
sion of this article is available at http://www.jem.org/cgi/content/full/
jem.20080099/DC1. 
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used to detect CD4  +  CD25  +  Foxp3  +   cells after in vivo depletions with anti-
CD25 (clone PC61). 
  Cell lines.     The highly tumorigenic and poorly immunogenic melanoma 
cell line B16/BL6 was used for tumor challenge and also as a stimulator for 
cytokine production in ELISPOT assays and cytokine bead array (CBA) as-
says. B16/BL6-expressing GM-CSF, here referred to as Gvax, was used for 
treatment of tumor-bearing mice. Both cell lines have been previously de-
scribed (  21  ). In addition, transgenic adenocarcinoma mouse prostate model 
(TRAMP)-C2 (  58  ), an epithelial tumor cell line derived from TRAMP, was 
used as negative control in ELISPOT assays and CBA assays. 
  Tumor challenge and treatments.     For most experiments, mice were 
treated as described in   Fig. 1 A  . Mice were challenged in the fl  ank intrader-
mally (i.d.) at day 0 with 20,000 B16/BL6 melanoma cells, and then treated 
or not treated with Gvax with or without anti  –  CTLA-4 mAb. 1 million ir-
radiated (15,000 rad) Gvax cells were injected i.d. (100   μ  l) in the contralat-
eral fl  ank on days 8, 11, and 14, while at the same time points 200, 100, and 
100   μ  g of anti  –  CTLA-4 were injected i.p. in 200   μ  l of PBS. For depletion 
experiments, mice also received 400   μ  g of anti-CD25 on day     4 (prophy-
lactic setting) or day 4 after tumor challenge (therapeutic setting). Mice were 
either monitored for tumor growth or killed for quantifi  cation of tumor in-
fi  ltrates and for functional and histological analysis. 
  Foxp3-directed T reg cell depletion.     Foxp3-DTR transgenic or litter-
mate mice were challenged with B16/BL6 melanoma at day 0 and treated 
with Gvax and anti  –  CTLA-4 on days 8, 11, and 14, as described in the pre-
vious section. To deplete Foxp3  +   T reg cells, mice were injected i.p. with 
900 ng of DT (Sigma-Aldrich) on day     1 and 0 (prophylactic setting) or on 
day 7 and 8 after tumor challenge (therapeutic setting). Although prelimi-
nary experiments suggested that DT signifi  cantly reduced the Foxp3  +   popu-
lation in     24 h, anti-CD25 administration takes     3  –  4 d to effi   ciently 
deplete the Foxp3  +   compartment. Thus, the time points for CD25- and 
Foxp3-directed depletion were selected to allow a signifi  cant reduction 
in the T reg cell compartment by the time of tumor challenge or Gvax/
    CTLA-4 treatment. 
  Phenotypic and functional studies.     14 d after tumor challenge, mice from 
diff  erent groups where killed and their lymphoid organs and tumors were har-
vested and analyzed by fl  ow cytometry for the expression of CD8, CD4, 
CD25, Foxp3, and the proliferation marker KI-67. To determine production 
of IL-2 and IFN-    , CD4  +   or CD8  +   T cells were isolated from mice and re-
stimulated in vitro with a mix of purifi  ed dendritic cells and B16/BL6 tumor 
or control TRAMP-C2 irrelevant tumor. 100,000 CD8  +   cells were incubated 
with 50,000 dendritic cells and 10,000 tumor cells for 24 h, and production of 
IL-2 and IFN-     was determined using an ELISPOT kit or a CBA kit (BD 
Biosciences) according to manufacturer  ’  s instruction. ELISPOT data are pre-
sented as the number of spots produced per 100,000 CD8  +   T cells in response 
to B16/BL6 tumor cells minus the spots detected in response to TRAMP-C2 
tumor cells, whereas the data for CBA is presented as picograms/milliliter of 
cytokines produced in response to B16/BL6 tumor cells minus that produced 
in response to TRAMP-C2. For analysis of CD8  +   pmel TCR responses, 
CD8  +   cells where purifi  ed from CD45.1  +  pmel  +   Tg mice by negative selection 
using Miltenyi beads and following the manufacturer  ’  s instructions. After pu-
rifi  cation, 10  6   pmel cells were transferred i.v. into mice treated as described 
in   Fig. 1 A  . pmel cells were detected by fl  ow cytometry by double gating on 
CD8  +   cells and the congenic donor marker CD45.1. 
  Isolation of TILs.     B16/BL6 melanoma tumors were dissected from mice 
and injected with 1 ml of a solution containing 0.2 mg/ml DNase and 1.67 
W  ü  nschU/ml Liberase in unsupplemented RPMI. Tumors were incubated 
at 37  °  C for 30 min, disaggregated, passed through a 40-    m fi  lter, and washed 
several times. A fi  coll gradient was performed to eliminate dead cells and tumor 
debris. TILs were analyzed by fl  ow cytometry for the expression of CD8, 
CD4, CD25, Foxp3, and the proliferation marker KI-67. Intratumor ratio of JEM VOL. 205, September 1, 2008 
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